Literature DB >> 28377420

Inequalities in access to genitourinary medicine clinics in the UK: results from a mystery shopper survey.

Elizabeth Foley1, Martina Furegato2, Gwenda Hughes2, Christopher Board3, Vanessa Hayden3, Timothy Prescott3, Eleanor Shone3, Rajul Patel4.   

Abstract

STUDY
DESIGN: This study investigated whether access to genitourinary medicine (GUM) clinics meets UK-recommended standards.
METHODS: In January 2014 and 2015, postal questionnaires about appointment and service characteristics were sent to lead clinicians of UK GUM clinics. In February 2014 and 2015, researchers posing as symptomatic and asymptomatic 'patients' contacted clinics by telephone, requesting to be seen. Clinic and patient characteristics associated with the offer of an appointment within 48 hours were examined using unadjusted and UK country and patient gender adjusted multivariable logistic regression analyses. In March 2015, a convenience sample (one in four) of clinics was visited by researchers with the same clinical symptoms. Ability to achieve a same-day consultation and waiting time were assessed.
RESULTS: In 2015, 90.8% of clinics offered symptomatic 'patients' an appointment within 48 hours when contacted by telephone, compared with 95.5% in 2014 (aOR=0.46 (0.26 to 0.83); p<0.01). The decline was greatest in women (96.0% to 90.1%; p<0.05), and clinics in England (96.2% to 90.7%; p<0.01). For asymptomatic patients, the proportion offered an appointment within 48 hours increased from 50.7% in 2014 to 74.5% in 2015 (aOR=3.06 (2.23 to 4.22); p<0.001), and in both men (58.2% to 90.8%; p<0.001) and women (49.0% to 59.6%; p<0.01). In adjusted analysis, asymptomatic women were significantly less likely to be offered an appointment than asymptomatic men (aOR=0.33 (0.23 to 0.45); p value<0.001). 95% of clinics were able to see symptomatic patients attending in person.
CONCLUSIONS: Access to GUM services has worsened for those with symptoms suggestive of an acute STI and is significantly poorer for asymptomatic women. This evidence may support the reintroduction of process targets. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  CLINICAL STI CARE; GENITOURINARY MEDICINE SERVICES; INFECTION CONTROL

Mesh:

Year:  2017        PMID: 28377420     DOI: 10.1136/sextrans-2016-052882

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  3 in total

1.  Finding sexual health aids after cancer: are cancer centers supporting survivors' needs?

Authors:  Sharon L Bober; Alexis L Michaud; Christopher J Recklitis
Journal:  J Cancer Surviv       Date:  2019-02-27       Impact factor: 4.442

2.  Assessment of the Potential of Vaccination to Combat Antibiotic Resistance in Gonorrhea: A Modeling Analysis to Determine Preferred Product Characteristics.

Authors:  Lilith K Whittles; Peter J White; Xavier Didelot
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

3.  Clinical presentation of asymptomatic and symptomatic women who tested positive for genital gonorrhoea at a sexual health service in Melbourne, Australia.

Authors:  Mario Martín-Sánchez; Christopher K Fairley; Jason J Ong; Kate Maddaford; Marcus Y Chen; Deborah A Williamson; Catriona S Bradshaw; Eric P F Chow
Journal:  Epidemiol Infect       Date:  2020-09-28       Impact factor: 2.451

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.